210 related articles for article (PubMed ID: 6906371)
21. [Bioavailability of drugs].
Finzi GF; Riolo U; Ghini R
Arch Sci Med (Torino); 1982; 139(1):51-5. PubMed ID: 7103709
[No Abstract] [Full Text] [Related]
22. Guidelines for the administration of commonly used intravenous drugs.
Rapp RP; Wermeling DP; Piecoro JJ
Drug Intell Clin Pharm; 1984 Mar; 18(3):217-32. PubMed ID: 6697884
[No Abstract] [Full Text] [Related]
23. Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.
Wagner JG
J Pharmacokinet Biopharm; 1976 Oct; 4(5):443-67. PubMed ID: 1003329
[No Abstract] [Full Text] [Related]
24. [Effect of the medicinal form and routes of administration of drugs on their pharmacokinetics and biological availability (review of the literature)].
Golovkin VA
Vrach Delo; 1987 Nov; (11):85-9. PubMed ID: 3326275
[No Abstract] [Full Text] [Related]
25. [Recent advance in predicting oral bioavailability].
Ma GL; Cheng YY
Yao Xue Xue Bao; 2006 Oct; 41(10):917-20. PubMed ID: 17184106
[No Abstract] [Full Text] [Related]
26. Legitimate indications for intramuscular injections.
Alper PR
Arch Intern Med; 1978 Nov; 138(11):1705-10. PubMed ID: 363081
[No Abstract] [Full Text] [Related]
27. IV bolus: effective, but potentially hazardous (continuing education credit).
Burman R; Berkowitz HS
Crit Care Nurse; 1986; 6(1):22-8. PubMed ID: 3633789
[No Abstract] [Full Text] [Related]
28. [Optimization of bioavailability of pharmacons].
Kata M; Aigner Z; Erös I
Acta Pharm Hung; 1998 Mar; 68(2):107-11. PubMed ID: 9592935
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the results of bioavailability studies of different drugs in humans.
Wichliński LM; Kanarkowski R; Krzyśko K
Acta Pol Pharm; 1986; 43(3):276-82. PubMed ID: 3788627
[No Abstract] [Full Text] [Related]
30. [Biologic availability of drugs in humans and animals].
Wichliński L
Pol Tyg Lek; 1975 Dec; 30(50):2111-2. PubMed ID: 1197106
[No Abstract] [Full Text] [Related]
31. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs.
Greenblatt DJ; von Moltke LL
J Clin Pharmacol; 2008 Nov; 48(11):1350-5. PubMed ID: 18757784
[TBL] [Abstract][Full Text] [Related]
32. [Effect of liver diseases on bioavailability and clearance of drugs].
Paumgartner G
Internist (Berl); 1980 Dec; 21(12):718-23. PubMed ID: 7009473
[No Abstract] [Full Text] [Related]
33. [Administration of drugs in infusions].
Honig C
Ned Tijdschr Geneeskd; 1972 Jan; 116(5):189-94. PubMed ID: 5028757
[No Abstract] [Full Text] [Related]
34. [Hygienic requirements in parenteral administration of drugs].
Chirurg; 1995 Aug; 66(8):suppl 185-6. PubMed ID: 7587535
[No Abstract] [Full Text] [Related]
35. The i.v. administration of drugs.
Norman J
Br J Anaesth; 1983 Nov; 55(11):1049-52. PubMed ID: 6416280
[No Abstract] [Full Text] [Related]
36. Safe intravenous practice.
Tinning R
Nurs Times; 1986 Jul 23-29; 82(30):40. PubMed ID: 3638619
[No Abstract] [Full Text] [Related]
37. Adding drugs to intravenous infusions.
Lancet; 1970 Sep; 2(7672):556-7. PubMed ID: 4195213
[No Abstract] [Full Text] [Related]
38. [Bioavailability and its significance in pharmacotherapy].
Wiela-Hojeńska A; Orzechowska-Juzwenko K
Pol Merkur Lekarski; 2003 Jan; 14(79):89-93. PubMed ID: 12712840
[TBL] [Abstract][Full Text] [Related]
39. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs.
Kipp JE
Int J Pharm; 2004 Oct; 284(1-2):109-22. PubMed ID: 15454302
[TBL] [Abstract][Full Text] [Related]
40. Oral bioavailability and first-pass effects.
Kwan KC
Drug Metab Dispos; 1997 Dec; 25(12):1329-36. PubMed ID: 9394021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
